This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Amgen Performance dei guadagni passati
Il passato criteri di controllo 0/6
Amgen's earnings have been declining at an average annual rate of -7.1%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 4.3% per year. Amgen's return on equity is 52.8%, and it has net margins of 10.1%.
Informazioni chiave
-7.1%
Tasso di crescita degli utili
-3.8%
Tasso di crescita dell'EPS
Biotechs Crescita del settore | 14.2% |
Tasso di crescita dei ricavi | 4.3% |
Rendimento del capitale proprio | 52.8% |
Margine netto | 10.1% |
Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Ripartizione dei ricavi e delle spese
Come Amgen guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Jun 24 | 30,934 | 3,130 | 7,207 | 5,374 |
31 Mar 24 | 29,532 | 3,763 | 6,716 | 5,040 |
31 Dec 23 | 28,190 | 6,717 | 6,166 | 4,755 |
30 Sep 23 | 26,833 | 7,566 | 5,464 | 4,574 |
30 Jun 23 | 26,582 | 7,979 | 5,411 | 4,607 |
31 Mar 23 | 26,190 | 7,917 | 5,444 | 4,533 |
31 Dec 22 | 26,323 | 6,552 | 5,414 | 4,434 |
30 Sep 22 | 26,330 | 6,835 | 5,267 | 4,458 |
30 Jun 22 | 26,384 | 6,576 | 5,285 | 4,768 |
31 Mar 22 | 26,316 | 5,723 | 5,342 | 4,811 |
31 Dec 21 | 25,979 | 5,893 | 5,368 | 4,819 |
30 Sep 21 | 25,767 | 5,609 | 5,716 | 4,700 |
30 Jun 21 | 25,484 | 5,746 | 5,757 | 4,340 |
31 Mar 21 | 25,164 | 7,085 | 5,668 | 4,222 |
31 Dec 20 | 25,424 | 7,264 | 5,730 | 4,207 |
30 Sep 20 | 24,987 | 7,352 | 5,470 | 4,290 |
30 Jun 20 | 24,301 | 7,299 | 5,347 | 4,229 |
31 Mar 20 | 23,966 | 7,675 | 5,312 | 4,189 |
31 Dec 19 | 23,362 | 7,842 | 5,150 | 4,116 |
30 Sep 19 | 23,395 | 8,067 | 5,196 | 3,986 |
30 Jun 19 | 23,562 | 7,958 | 5,266 | 3,911 |
31 Mar 19 | 23,750 | 8,075 | 5,359 | 3,856 |
31 Dec 18 | 23,747 | 8,394 | 5,332 | 3,737 |
30 Sep 18 | 23,319 | 2,202 | 5,268 | 3,598 |
30 Jun 18 | 23,188 | 2,364 | 5,145 | 3,549 |
31 Mar 18 | 22,939 | 2,219 | 5,001 | 3,553 |
31 Dec 17 | 22,849 | 1,979 | 4,870 | 3,562 |
30 Sep 17 | 23,012 | 8,178 | 4,824 | 3,597 |
30 Jun 17 | 23,050 | 8,174 | 4,898 | 3,710 |
31 Mar 17 | 22,928 | 7,893 | 4,981 | 3,737 |
31 Dec 16 | 22,991 | 7,722 | 5,120 | 3,840 |
30 Sep 16 | 22,562 | 7,587 | 5,164 | 3,791 |
30 Jun 16 | 22,474 | 7,433 | 5,164 | 3,920 |
31 Mar 16 | 22,156 | 7,216 | 5,032 | 3,984 |
31 Dec 15 | 21,662 | 6,939 | 4,855 | 4,006 |
30 Sep 15 | 21,457 | 6,433 | 4,778 | 4,162 |
30 Jun 15 | 20,765 | 5,814 | 4,747 | 4,061 |
31 Mar 15 | 20,575 | 5,708 | 4,723 | 4,115 |
31 Dec 14 | 20,063 | 5,158 | 4,720 | 4,248 |
30 Sep 14 | 19,743 | 4,885 | 4,851 | 4,312 |
30 Jun 14 | 19,460 | 5,009 | 4,887 | 4,283 |
31 Mar 14 | 18,959 | 4,720 | 5,007 | 4,232 |
31 Dec 13 | 18,676 | 5,081 | 5,142 | 4,083 |
30 Sep 13 | 17,980 | 4,848 | 5,012 | 3,772 |
Guadagni di qualità: AM1 has a large one-off gain of $1.0B impacting its last 12 months of financial results to 30th June, 2024.
Margine di profitto in crescita: AM1's current net profit margins (10.1%) are lower than last year (30%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: AM1's earnings have declined by 7.1% per year over the past 5 years.
Accelerare la crescita: AM1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Guadagni vs Settore: AM1 had negative earnings growth (-60.8%) over the past year, making it difficult to compare to the Biotechs industry average (2.8%).
Rendimento del capitale proprio
ROE elevato: Whilst AM1's Return on Equity (52.83%) is outstanding, this metric is skewed due to their high level of debt.